D. Daniely

Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma

T. Spektor, Haiming Chen, J. Berenson, 2021, European journal of haematology.

Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma

N. Xu, T. Spektor, Haiming Chen, 2020, British journal of haematology.

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

T. Spektor, Haiming Chen, J. Berenson, 2021, Leukemia.

A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.

T. Spektor, J. Berenson, J. Hrom, 2022, Experimental hematology.